OncLive and Targeted Oncology: Drug yields long-lasting benefits to treat PEComa tumors
OncLive and Targeted Oncology covered research presented by the University of Cincinnati's Thomas Herzog that found patients with perivascular epithelioid sarcoma (PEComa) of gynecologic or peritoneal origin experienced rapid, durable responses when treated with the drug nab-sirolimus.
At the 2024 SGO Annual Meeting on Women's Cancer, Herzog presented results from a subgroup analysis of the phase 2 AMPECT trial. Nab-sirolimus is the first and only FDA-approved treatment for advanced PEComa.
"The median time to response was extremely fast, about 1.4 months, and the duration of response was a little over 36 months," Herzog, MD, a University of Cincinnati Cancer Center member, the Paul and Carolyn Flory Professor in Gynecologic Oncology in the UC College of Medicine and director of UC Health’s Gynecologic Cancer Disease Center, told Targeted Oncology. "It is important to remember these responses occur often rapidly, and they are quite durable."
Watch the Targeted Oncology video.
Featured photo at top of Thomas Herzog. Photo provided.
Related Stories
High Court offers protections for therapy speech
April 5, 2026
Jennifer Bard, a professor in the Donald P. Klekamp College of Law and the UC Department of Internal Medicine, spoke with journalists about the US Supreme Court ruling granting first amendment protections for speech offered during therapy sessions.
Scientists discover how snakes stand upright without limbs
April 3, 2026
Smithsonian magazine highlights a study co-authored by UC Professor Bruce Jayne, an expert in snake locomotion, about how snakes stand upright without arms or legs.
On track: Hoffman Honors Scholar studies public transit
April 2, 2026
Public transit is where Zane Sawyer’s lifelong passion for travel meets his commitment to making an impact. The University of Cincinnati first-year geography major in the College of Arts & Sciences and member of the second cohort of Hoffman Honors Scholars (HHS) has hit the ground running, designing a research project intended to capture both how public transit works and how its users perceive it.